PPARγ-PI3K/AKT-NO signal pathway is involved in cardiomyocyte hypertrophy induced by high glucose and insulin

Journal of Diabetes and its Complications

Volumn 29, Issue 6, 2015, Pages 755-760

  Peng, Xiaofeng ^a   Chen, Rongchun ^a   Wu, Yang ^a   Huang, Bo ^a   Tang, Cuiping ^a   Chen, Jiafei ^a   Wang, Quanhua ^a   Wu, Qin ^b   Yang, Junqing ^a   Qiu, Hongmei ^a   Jiang, Qingsong ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b ZUNYI MEDICAL UNIVERSITY   (China)

Author keywords

Cardiomyocyte hypertrophy; High glucose and insulin; NO; Peroxisome proliferator activated receptor ; PI3K AKT

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; ATRIAL NATRIURETIC FACTOR; GLUCOSE; INSULIN; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; ROSIGLITAZONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAIMAN; CELL SURFACE; CONTROLLED STUDY; ENZYME ACTIVITY; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SPECTROPHOTOMETRY; WESTERN BLOTTING; ANIMAL; CARDIAC MUSCLE CELL; CELL CULTURE; COMPLICATION; DRUG EFFECTS; HYPERGLYCEMIA; HYPERINSULINISM; HYPERTROPHY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT;

ANIMALS; CELLS, CULTURED; GLUCOSE; HYPERGLYCEMIA; HYPERINSULINISM; HYPERTROPHY; INSULIN; MYOCYTES, CARDIAC; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3-KINASES; PPAR GAMMA; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION;

EID: 84942827206     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2015.04.012     Document Type: Article

References (30)

1. Ahmadian, M., Suh, J.M., Hah, N., Liddle, C., Atkins, A. R., Downes,M., et al. (2013). PPAR γ signaling andmetabolism: The good, the bad and the future. Nature Medicine, 19, 557-566.
2. Anandharajan, R., Jaiganesh, S., Shankernarayanan, N. P., Viswakarma, R. A., & Balakrishnan, A. (2006). In vitro glucose uptake activity of Aegles marmelos and Syzygium cumini by activation of Glut-4, PI3 kinase and PPAR gamma in L6 myotubes. Phytomedicine, 13, 434-441.
3. Bell, D., & McDermott, B. J. (2005). Effects of rosiglitazone and interactions with growth-regulating factors in ventricular cell hypertrophy. European Journal of Pharmacology, 508, 69-76.
4. Berger, J. P., Akiyama, T. E., & Meinke, P. T. (2005). PPARs: Therapeutic targets for metabolic disease. Trends in Pharmacological Sciences, 26, 244-251.
5. Chavali, V., Tyagi, S. C., & Mishra, P. K. (2013). Predictors and prevention of diabetic cardiomyopathy. Diabetes Metab Syndr Obes., 6, 151-160.
6. Cheang,W. S., Fang, X., & Tian, X. Y. (2013). Pleiotropic effects of peroxisome proliferatoractivated receptor γ and d in vascular diseases. Circulation Journal, 77, 2664-2671.
7. Chen, W., Li, Y. M., & Yu, M. H. (2010). Astragalus polysaccharides inhibited diabetic cardiomyopathy in hamsters depending on suppression of heart chymase activation. Journal of Diabetes and its Complications, 24, 199-208.
8. Ding, G., Fu, M., Qin, Q., Lewis, W., Kim, H. W., Fukai, T., et al. (2007). Cardiac peroxisome proliferator-activated receptor gamma is essential in protecting cardiomyocytes from oxidative damage. Cardiovascular Research, 76, 269-279.
9. Duan, S. Z., Ivashchenko, C. Y.,Whitesall, S. E.,D'Alecy, L.G., Duquaine,D. C., Brosius, F. C., et al. (2007). Hypotension, lipodystrophy, and insulin resistance in generalized PPARγ-deficient mice rescued from embryonic lethality. The Journal of Clinical Investigation, 117, 812-822.
10. Gao, F., Gao, E., Yue, T. L., Ohlstein, E. H., Lopez, B. L., Christopher, T. A., et al. (2002). Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischemia-reperfusion: The roles of PI3-kinase, Akt, and endothelial nitric oxide synthase phosphorylation. Circulation, 105, 1497-1502.
11. Garçon, F., Patton, D. T., Emery, J. L., Hirsch, E., Rottapel, R., Sasaki, T., et al. (2008). CD28 provides T-cell costimulation and enhances PI3K activity at the immune synapse independently of its capacity to interact with the p85/p110 heterodimer. Blood, 111, 1464-1471.
12. Honda, A., Matsuura, K., Fukushima, N., Tsurumi, Y., Kasanuki, H., Hagiwara, N., et al. (2009). Telmisartan induces proliferation of human endothelial progenitor cells via PPARgamma-dependent PI3K/Akt pathway. Atherosclerosis, 205, 376-384.
13. Hsueh, W. A., Jackson, S., & Law, R. E. (2001). Control of vascular cell proliferation and migration by PPAR-gamma: A new approach to the macrovascular complications of diabetes. Diabetes Care, 24, 392-397.
14. Hu, T. P., Xu, F. P., Li,Y. J.,&Luo, J.D. (2006). Simvastatin inhibits leptin-induced hypertrophy in cultured neonatal rat cardiomyocytes. Acta Pharmacologica Sinica, 27, 419-422.
15. Jung, U. J., Torrejon, C., Chang, C. L., Hamai, H., Worgall, T. S., Deckelbaum, R. J., et al. (2012). Fatty acids regulate endothelial lipase and inflammatory markers in macrophages and in mouse aorta: A role for PPARγ. Arteriosclerosis, Thrombosis, and Vascular Biology, 32, 2929-2937.
16. Kilter, H., Werner, M., Roggia, C., Reil, J. C., Schäfers, H. J., Kintscher, U., et al. (2009). The PPAR-gamma agonist rosiglitazone facilitates Akt rephosphorylation and inhibits apoptosis in cardiomyocytes during hypoxia/reoxygenation. Diabetes, Obesity & Metabolism, 11, 1060-1067.
17. Kis, A., Murdoch, C., & Zhang, M. (2009). Defective peroxisomal proliferators activated receptor gamma activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice. European Journal of Heart Failure, 11, 533-541.
18. Li, R., Zhang, H., Wang, W., Wang, X., Huang, Y., Huang, C., et al. (2010). Vascular insulin resistance in prehypertensive rats: role of PI3-kinase/Akt/eNOS signaling. European Journal of Pharmacology, 628, 140-147.
19. Liang, C., Ren, Y., Tan, H., He, Z., Jiang, Q., Wu, J., et al. (2009). Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end products. British Journal of Pharmacology, 158, 1865-1873.
20. Liao, Y., Takashima, S., & Zhao, H. (2006). Control of plasma glucose with alphaglucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice. Cardiovascular Research, 70, 107-116.
21. Liu, Y., Tian, X. Y., Mao, G., Fang, X., Fung, M. L., Shyy, J. Y., et al. (2012). Peroxisome proliferator-activated receptor-gamma ameliorates pulmonary arterial hypertension by inhibiting 5-hydroxytryptamine 2B receptor. Hypertension, 60, 1471-1478.
22. Mehrabi, M. R., Thalhammer, T., Haslmayer, P., Glogar, H. D., Wieselthaler, G., Humpeler, S., et al. (2002). The peroxisome proliferator-activated receptor gamma (PPARgamma) is highly expressed in human heart ventricles. Biomedicine & Pharmacotherapy, 56, 407-410.
23. Miao, B., Skidan, I., Yang, J., Lugovskoy, A., Reibarkh, M., Long, K., et al. (2010). Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains. Proceedings of the National Academy of Sciences of the United States of America, 107, 20126-20131.
24. Rangwala, S. M., Rhoades, B., Shapiro, J. S., Rich, A. S., Kim, J. K., Shulman, G. I., et al. (2003). Genetic modulation of PPARgamma phosphorylation regulates insulin sensitivity. Developmental Cell, 5, 657-663.
25. Ryan, M. J., Didion, S. P., Mathur, S., Faraci, F. M., & Sigmund, C. D. (2004). PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension, 43, 661-666.
26. Wahli, W. (2002). Peroxisome proliferator-activated receptors (PPARs): From metabolic control to epidermal wound healing. Swiss Medical Weekly, 132, 83-91.
27. Wang, M., Wang, J., Tan, R., Wu, Q., Qiu, H., Yang, J., et al. (2013). Effect of berberine on PPAR α/NO activation in high glucose-and insulin-induced cardiomyocyte hypertrophy. Evidence-based Complementary and Alternative Medicine, 2013, http://dx.doi.org/10.1155/2013/285489.
28. Way, J. M., Görgün, C. Z., Tong, Q., Uysal, K. T., Brown, K. K., Harrington, W. W., et al. (2001). Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. The Journal of Biological Chemistry, 276, 25651-25653.
29. Yasuda, S., Kobayashi, H., Iwasa, M., Kawamura, I., Sumi, S., Narentuoya, B., et al. (2009). Antidiabetic drug pioglitazone protects the heart via activation of PPAR-γ receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction. American Journal of Physiology. Heart and Circulatory Physiology, 296, 1558-1565.
30. Zhang, L., Xie, P., Wang, J., Yang, Q., Fang, C., Zhou, S., et al. (2010). Impaired peroxisome proliferator-activated receptor-gamma contributes to phenotypic modulation of vascular smooth muscle cells during hypertension. The Journal of Biological Chemistry, 285, 13666-13677.